You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: May 17, 2025

Drugs in MeSH Category Serotonin 5-HT2 Receptor Antagonists


✉ Email this page to a colleague

« Back to Dashboard


Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sunovion Pharms Inc LATUDA lurasidone hydrochloride TABLET;ORAL 200603-004 Apr 26, 2012 AB RX Yes No ⤷  Try for Free ⤷  Try for Free Y ⤷  Try for Free
Aurobindo Pharma Ltd LURASIDONE HYDROCHLORIDE lurasidone hydrochloride TABLET;ORAL 208045-001 Mar 10, 2023 AB RX No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Sunovion Pharms Inc LATUDA lurasidone hydrochloride TABLET;ORAL 200603-003 Dec 7, 2011 AB RX Yes No ⤷  Try for Free ⤷  Try for Free Y ⤷  Try for Free
Sunovion Pharms Inc LATUDA lurasidone hydrochloride TABLET;ORAL 200603-005 Jul 12, 2013 AB RX Yes No ⤷  Try for Free ⤷  Try for Free Y ⤷  Try for Free
Watson Labs Teva LURASIDONE HYDROCHLORIDE lurasidone hydrochloride TABLET;ORAL 208016-004 Feb 2, 2021 DISCN No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Janssen Pharms INVEGA SUSTENNA paliperidone palmitate SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 022264-002 Jul 31, 2009 AB RX Yes No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Janssen Pharms INVEGA TRINZA paliperidone palmitate SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 207946-001 May 18, 2015 RX Yes Yes ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Serotonin 5-HT2 Receptor Antagonists Market Analysis and Financial Projection

The market for serotonin 5-HT2 receptor antagonists is evolving rapidly, driven by expanding therapeutic applications, patent innovations, and increasing demand for treatments targeting neurological and psychiatric disorders. Here's a detailed analysis:


Market Growth and Drivers

  • Projected Expansion: The broader 5-hydroxytryptamine receptor market, which includes 5-HT2 antagonists, is projected to grow from $1.2 billion in 2024 to $2.5 billion by 2033, with a CAGR of 9.2%[4]. This growth is fueled by rising mental health disorders, such as schizophrenia, depression, and Parkinson’s disease psychosis[4][14].
  • Key Therapeutic Areas:
    • Neuropsychiatric Disorders: Pimavanserin, a 5-HT2A inverse agonist, is FDA-approved for hallucinations in Parkinson’s psychosis[14].
    • Oncology Support: 5-HT3 antagonists (a related class) dominate the $6.3 billion antiemetic market for chemotherapy-induced nausea, illustrating the broader potential of serotonin modulators[12].
    • Emerging Applications: 5-HT2B receptor antagonists are being explored for fibrosis, gastrointestinal disorders, and cancer[10].

Patent Landscape and Innovation

  • Recent Developments:
    • 2A Biosciences patented novel 5-HT2A/2C agonists in 2024 for conditions like Crohn’s disease, schizophrenia, and traumatic brain injury[2].
    • Tricyclic Derivatives: Patents like AU2020295685A1 cover new tricyclic compounds targeting 5-HT2 receptors[7], while EP3109237A1 (withdrawn) focused on 5-HT2B antagonists[9].
  • Challenges in Selectivity: High homology between 5-HT2A and 5-HT2C receptors complicates drug design, leading to non-selective agents like LSD. Advances in receptor crystallography are aiding selective compound development[1][10].

Competitive Pressures and Generics

  • Patent Expiries: The looming expiration of key patents (e.g., ondansetron for 5-HT3 in 2006[5]) highlights the impact of generics. However, "supergenerics" with improved formulations (e.g., nanoparticle-bound paclitaxel) are mitigating revenue loss[5].
  • Clinical Setbacks: Several 5-HT2A antagonists, including volinanserin and pruvanserin, were discontinued due to inadequate efficacy[6][17], underscoring the high risk in drug development.

Regional Dynamics

  • Asia-Pacific Dominance: Holds the largest market share due to high cancer prevalence and chemotherapy adoption[12].
  • North American Innovation: Leading in R&D, with companies like Acadia Pharmaceuticals advancing 5-HT2A agents (e.g., pimavanserin)[14].

Future Outlook

  • Personalized Medicine: Genetic profiling and biased signaling research (e.g., 5-HT2B in pancreatic cancer[10]) are opening avenues for targeted therapies.
  • Collaborative R&D: Partnerships between biotech firms and academia aim to overcome selectivity hurdles and explore novel indications like fibrotic diseases[10].

Highlight: "The global 5-hydroxytryptamine receptor market is expected to double by 2033, with 5-HT2 antagonists playing a pivotal role in neurology and oncology"[4].


Key Takeaways:

  • Market growth is robust but hinges on overcoming receptor selectivity and clinical attrition.
  • Patent filings remain active, with a focus on polypharmacology (targeting multiple 5-HT subtypes) and novel formulations.
  • Regional expansion in Asia-Pacific and therapeutic diversification into fibrosis/cancer will shape future dynamics.

References

  1. https://www.jneurosci.org/content/43/45/7472
  2. https://www.bioworld.com/articles/712559-new-5-ht2a-and-5-ht2c-receptor-agonists-disclosed-in-2a-biosciences-patent
  3. https://pubmed.ncbi.nlm.nih.gov/9401775/
  4. https://www.verifiedmarketreports.com/product/5-hydroxytryptamine-receptor-market/
  5. https://www.ufrgs.br/imunovet/molecular_immunology/anticancer.html
  6. https://pmc.ncbi.nlm.nih.gov/articles/PMC3630942/
  7. https://patents.google.com/patent/AU2020295685A1/en
  8. https://pubmed.ncbi.nlm.nih.gov/9877220/
  9. https://patents.google.com/patent/EP3109237A1/en
  10. https://pmc.ncbi.nlm.nih.gov/articles/PMC7909583/
  11. https://patents.google.com/patent/WO2002036113A1/en
  12. https://www.industryarc.com/Report/19738/5ht3-receptor-antagonists-market.html
  13. https://patents.justia.com/patent/20030083325
  14. https://www.businesswire.com/news/home/20210310005551/en/Pimavanserin-A-Selective-Serotonin-Inverse-Agonist-and-Antagonist-Preferentially-Targeting-5-HT2A-Receptors---Global-Emerging-Insights-and-Market-Forecast-to-2030---ResearchAndMarkets.com
  15. https://patents.google.com/patent/US9801856B2/en
  16. https://patents.google.com/patent/US20030083325A1/en
  17. https://pubmed.ncbi.nlm.nih.gov/26609882/
  18. https://meshb.nlm.nih.gov/record/ui?ui=D058830
Last updated: 2025-03-24

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.